by Alison Bass | Jul 5, 2011 | antipsychotic drugs, conflicts of interest, pharmaceutical industry, university industry collaboration
Harvard Medical School finally wrapped up its three-year-old investigation of Dr. Joseph Biederman and two colleagues accused of failing to disclose extensive financial conflicts of interest, with essentially a slap on the wrist. In 2008, Congressional investigators...
by Alison Bass | Jun 28, 2011 | conflicts of interest, pharmaceutical industry
Two quick notes: the Project on Government Oversight (POGO) has posted a helpful FAQ on corporate-funded medical ghostwriting. As POGO investigator Paul Thacker writes: “We hope this [FAQ] will answer any questions you might have on this very disturbing practice...
by Alison Bass | Jun 27, 2011 | biotech industry, conflicts of interest, drug marketing, health care costs, medical devices, pharmaceutical industry
A page-one story in The Boston Globe today spotlights the Massachusetts biotech industry’s effort to block a key piece of President Obama’s health care overhaul: the creation of an independent payment advisory board (IPAB) that would make recommendations...
by Alison Bass | Jun 14, 2011 | pharmaceutical industry, Uncategorized, university industry collaboration
I was planning to blog about Pfizer’s new $100 million partnership with several Boston-area medical centers and its potential downsides. But before I could get around to doing that, I was invited to talk about the deal on WGBH-TV’s Greater Boston show...
by Alison Bass | May 13, 2011 | antidepressants, ghostwriting, pharmaceutical industry
In his latest blog, Paul Thacker, an investigator for the Project on Government Oversight (POGO) and former aide to Senator Charles Grassley, struggles to understand how Dr. Stan Kutcher, a psychiatrist turned politician in Canada, could possibly say that Paxil study...
